Hailiang Education Group Inc. (HLG) Reaches $56.56 High on Feb, 15; Verastem (VSTM) Sellers Decreased By 2.91% Their Shorts

February 15, 2018 - By Hazel Jackson

The stock of Hailiang Education Group Inc. (NASDAQ:HLG) reached all time high today, Feb, 15 and still has $59.39 target or 5.00% above today’s $56.56 share price. This indicates more upside for the $1.46B company. This technical setup was reported by Barchart.com. If the $59.39 PT is reached, the company will be worth $72.90M more. The stock increased 1.76% or $0.98 during the last trading session, reaching $56.56. About 44,845 shares traded. Hailiang Education Group Inc. (NASDAQ:HLG) has risen 5.27% since February 15, 2017 and is uptrending. It has underperformed by 11.43% the S&P500.

Verastem Incorporated (NASDAQ:VSTM) had a decrease of 2.91% in short interest. VSTM’s SI was 975,500 shares in February as released by FINRA. Its down 2.91% from 1.00M shares previously. With 569,000 avg volume, 2 days are for Verastem Incorporated (NASDAQ:VSTM)’s short sellers to cover VSTM’s short positions. The SI to Verastem Incorporated’s float is 2.99%. The stock decreased 2.12% or $0.07 during the last trading session, reaching $3.23. About 151,572 shares traded. Verastem, Inc. (NASDAQ:VSTM) has risen 71.53% since February 15, 2017 and is uptrending. It has outperformed by 54.83% the S&P500.

Among 10 analysts covering Verastem (NASDAQ:VSTM), 5 have Buy rating, 0 Sell and 5 Hold. Therefore 50% are positive. Verastem had 29 analyst reports since September 9, 2015 according to SRatingsIntel. H.C. Wainwright maintained it with “Buy” rating and $17 target in Thursday, September 17 report. As per Friday, March 24, the company rating was maintained by H.C. Wainwright. The stock of Verastem, Inc. (NASDAQ:VSTM) has “Buy” rating given on Tuesday, July 25 by Oppenheimer. The firm earned “Outperform” rating on Tuesday, September 29 by Raymond James. Oppenheimer maintained Verastem, Inc. (NASDAQ:VSTM) rating on Monday, June 26. Oppenheimer has “Buy” rating and $600 target. The firm has “Buy” rating given on Tuesday, August 8 by Oppenheimer. Jefferies downgraded Verastem, Inc. (NASDAQ:VSTM) on Tuesday, September 29 to “Hold” rating. UBS downgraded the stock to “Neutral” rating in Tuesday, September 29 report. The rating was maintained by Jefferies on Monday, June 26 with “Hold”. The stock has “Neutral” rating by Roth Capital on Monday, September 28.

Investors sentiment increased to 1.4 in 2017 Q3. Its up 0.23, from 1.17 in 2017Q2. It increased, as 6 investors sold Verastem, Inc. shares while 19 reduced holdings. 19 funds opened positions while 16 raised stakes. 12.96 million shares or 49.25% more from 8.68 million shares in 2017Q2 were reported. Georgia-based Advisory Services Limited Liability Company has invested 0.01% in Verastem, Inc. (NASDAQ:VSTM). Highbridge Capital Mgmt Lc holds 100,000 shares. Acadian Asset Management Limited Company owns 42,410 shares for 0% of their portfolio. Alpine Woods Capital Ltd Com invested in 0.01% or 50,040 shares. Goldman Sachs Group Inc reported 0% of its portfolio in Verastem, Inc. (NASDAQ:VSTM). Raymond James And Assoc, Florida-based fund reported 58,406 shares. Clarivest Asset Limited Liability accumulated 89,700 shares. Northern Trust Corporation stated it has 66,519 shares. 579 are owned by Tower Rech Limited Liability (Trc). Deutsche Comml Bank Ag owns 0% invested in Verastem, Inc. (NASDAQ:VSTM) for 224,591 shares. Stifel Fincl stated it has 370,920 shares. Lpl Ltd Liability invested in 0% or 19,494 shares. Group One Trading Ltd Partnership accumulated 0% or 52,579 shares. Citadel Advsrs Limited Liability Company has invested 0% in Verastem, Inc. (NASDAQ:VSTM). Morgan Stanley holds 0% of its portfolio in Verastem, Inc. (NASDAQ:VSTM) for 5,538 shares.

Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing drugs for the treatment of cancer. The company has market cap of $163.24 million. The Company’s programs target the focal adhesion kinase and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. It currently has negative earnings. The Company’s lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>